PubMed

Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis--practical aspects at the bedside and patient identification.

Laterre PF, Wittebole X.

Crit Care. 2003 Dec;7(6):445-50. Epub 2003 Jun 30. Review.PMID: 14624684 [PubMed - indexed for MEDLINE]Related articlesFree article

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.

Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent JL.

Crit Care. 2003 Apr;7(2):155-63. Epub 2003 Feb 28. Review.PMID: 12720562 [PubMed - indexed for MEDLINE]Related articlesFree article

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.

Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes J.

Crit Care Med. 2005 Oct;33(10):2266-77.PMID: 16215381 [PubMed - indexed for MEDLINE]Related articles

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.

Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR; PROWESS Investigators.

Crit Care Med. 2003 Jan;31(1):12-9.PMID: 12544987 [PubMed - indexed for MEDLINE]Related articles

Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.

De Backer D.

Drug Saf. 2007;30(11):995-1010. Review.PMID: 17973539 [PubMed - indexed for MEDLINE]Related articles

Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis.

McCoy C.

Expert Opin Drug Saf. 2004 Nov;3(6):625-37. Review.PMID: 15500421 [PubMed - indexed for MEDLINE]Related articles

Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.

Bernard GR, Margolis BD, Shanies HM, Ely EW, Wheeler AP, Levy H, Wong K, Wright TJ; Extended Evaluation of Recombinant Human Activated Protein C United States Investigators.

Chest. 2004 Jun;125(6):2206-16.PMID: 15189943 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.

Barie PS, Hydo LJ, Shou J, Eachempati SR.

Surg Infect (Larchmt). 2006;7 Suppl 2:S77-80. Review.PMID: 16895513 [PubMed - indexed for MEDLINE]Related articles

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.

Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, McL Booth FV.

Surgery. 2006 Nov;140(5):726-39. Corrected and republished in: Surgery. 2007 Apr;141(4):548-61. PMID: 17084715 [PubMed - indexed for MEDLINE]Related articles

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.

Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, Booth FV.

Surgery. 2007 Apr;141(4):548-61.PMID: 17431957 [PubMed - indexed for MEDLINE]Related articles

Drotrecogin alfa (activated) in the treatment of severe sepsis.

Vincent JL.

Curr Drug Saf. 2007 Sep;2(3):227-31. Review.PMID: 18690972 [PubMed - indexed for MEDLINE]Related articles

Drotrecogin alfa (activated) treatment in severe sepsis: a "journal club" review of the global ENHANCE trial.

Farmer JC.

Crit Care Med. 2005 Oct;33(10):2428-31. No abstract available. PMID: 16215411 [PubMed - indexed for MEDLINE]Related articles

Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.

Ridley S, Lwin A, Wyncoll D, Lippett S, Watson D, Gunning K, Higgins D.

Eur J Anaesthesiol. 2008 Mar;25(3):211-6. Epub 2007 Nov 22.PMID: 18031590 [PubMed - indexed for MEDLINE]Related articles

Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.

Green C, Dinnes J, Takeda A, Shepherd J, Hartwell D, Cave C, Payne E, Cuthbertson BH.

Health Technol Assess. 2005 Mar;9(11):1-126, iii-iv.PMID: 15774234 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C.

Yan SB, Nelson DR.

Crit Care Med. 2004 May;32(5 Suppl):S239-46.PMID: 15118525 [PubMed - indexed for MEDLINE]Related articles

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group.

N Engl J Med. 2005 Sep 29;353(13):1332-41.PMID: 16192478 [PubMed - indexed for MEDLINE]Related articlesFree article

Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.

Kanji S, Perreault MM, Chant C, Williamson D, Burry L.

Intensive Care Med. 2007 Mar;33(3):517-23. Epub 2007 Feb 15.PMID: 17325837 [PubMed - indexed for MEDLINE]Related articles

Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.

[No authors listed]

Prescrire Int. 2007 Feb;16(87):7-9.PMID: 17323514 [PubMed - indexed for MEDLINE]Related articles

Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis.

Macias WL, Dhainaut JF, Yan SC, Helterbrand JD, Seger M, Johnson G 3rd, Small DS.

Clin Pharmacol Ther. 2002 Oct;72(4):391-402.PMID: 12386641 [PubMed - indexed for MEDLINE]Related articles

Safety of drotrecogin alfa (activated) in surgical patients with severe sepsis.

Fry DE, Beilman G, Johnson S, Williams MD, Rodman G, Booth FV, Bates BM, McCollam JS, Lowry SF; PROWESS Surgical Evaluation Committee.

Surg Infect (Larchmt). 2004 Fall;5(3):253-9.PMID: 15684796 [PubMed - indexed for MEDLINE]Related articles